Shilpa Medicare Ltd
NSE:SHILPAMED
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
317.6
901.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SHILPAMED stock under the Base Case scenario is 1 256.17 INR. Compared to the current market price of 873.25 INR, Shilpa Medicare Ltd is Undervalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Shilpa Medicare Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SHILPAMED cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Shilpa Medicare Ltd
Balance Sheet Decomposition
Shilpa Medicare Ltd
Current Assets | 8.8B |
Cash & Short-Term Investments | 332.9m |
Receivables | 4B |
Other Current Assets | 4.5B |
Non-Current Assets | 22.2B |
Long-Term Investments | 462.7m |
PP&E | 16B |
Intangibles | 5.1B |
Other Non-Current Assets | 664.7m |
Current Liabilities | 6.9B |
Accounts Payable | 1.7B |
Other Current Liabilities | 5.2B |
Non-Current Liabilities | 5.9B |
Long-Term Debt | 5.6B |
Other Non-Current Liabilities | 297.3m |
Earnings Waterfall
Shilpa Medicare Ltd
Revenue
|
11.8B
INR
|
Cost of Revenue
|
-4.1B
INR
|
Gross Profit
|
7.7B
INR
|
Operating Expenses
|
-6.1B
INR
|
Operating Income
|
1.6B
INR
|
Other Expenses
|
-1.2B
INR
|
Net Income
|
447.6m
INR
|
Free Cash Flow Analysis
Shilpa Medicare Ltd
INR | |
Free Cash Flow | INR |
Shilpa Medicare Ltd. reported Q1 FY 2025 revenues of INR 302 crores, a 15% year-on-year growth driven by its formulation business in emerging markets and licensing segments. The gross profit margin improved to 68%, up from 66% last year. The EBITDA surged 66% to INR 83 crores, lifting margins from 19% to 28%. Net debt reduced significantly from INR 912 crores to INR 514 crores. The company foresees continued momentum with efficient cost management and anticipates growth in the biologics and licensing areas alongside ongoing R&D investments and strategic partnerships.
What is Earnings Call?
SHILPAMED Profitability Score
Profitability Due Diligence
Shilpa Medicare Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Shilpa Medicare Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
SHILPAMED Solvency Score
Solvency Due Diligence
Shilpa Medicare Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Shilpa Medicare Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SHILPAMED Price Targets Summary
Shilpa Medicare Ltd
According to Wall Street analysts, the average 1-year price target for SHILPAMED is 1 326 INR with a low forecast of 1 313 INR and a high forecast of 1 365 INR.
Dividends
Current shareholder yield for SHILPAMED is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.
Contact
IPO
Employees
Officers
The intrinsic value of one SHILPAMED stock under the Base Case scenario is 1 256.17 INR.
Compared to the current market price of 873.25 INR, Shilpa Medicare Ltd is Undervalued by 30%.